ALLR

Allarity Therapeutics, Inc. (ALLR) - Q3 2025 10-Q Summary

Business Context and Reporting Period

Allarity Therapeutics, Inc. is a clinical-stage precision medicine pharmaceutical company focused on developing anti-cancer therapeutics, primarily its lead candidate stenoparib, using its proprietary Drug Response Predictor (DRP®) technology. This report covers the quarterly period ended September 30, 2025. The Company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. As of November 13, 2025, there were 15,811,886 shares of common stock outstanding.

Key Financial Metrics

Note: The Company has no revenue. Operating expenses consist of Research & Development ($1.20M for Q3; $4.93M YTD) and General & Administrative ($1.32M for Q3; $4.76M YTD).

Material Changes vs. Prior Period

• Net Loss Reduction: The net loss for the nine months ended September 30, 2025, was $7.86 million, a significant decrease from $17.06 million in the same period in 2024. This improvement is largely due to the absence of a $9.70 million impairment of intangible assets recorded in 2024 and a $2.68 million gain on the change in fair value of derivative liabilities in 2024 which did not recur.
• Operating Expenses: Total operating expenses decreased by $10.24 million year-over-year for the nine-month period, driven primarily by the non-recurring impairment charge in the prior year.
• Foreign Exchange: The Company recorded a foreign exchange gain of $1.31 million for the nine months ended September 30, 2025, compared to a gain of $0.07 million in the prior year period.
• Capital Structure: The Company completed two reverse stock splits in 2024 (1-for-20 and 1-for-30). All historical share data has been retroactively adjusted.

Guidance, Outlook, and Risks

• Liquidity: Management estimates that existing cash of $16.9 million is sufficient to fund operations for at least the next 12 months. However, the Company has an accumulated deficit of $126.8 million and continues to incur losses.
• Recent Developments:
  • FDA Fast Track: Received Fast Track designation for stenoparib for advanced ovarian cancer (August 2025).
  • Capital Raises: Completed a private placement (PIPE) in September 2025 raising approximately $2.5 million. The At-The-Market (ATM) facility was fully utilized and terminated in March 2025.
  • Share Repurchase: Initiated a $5 million share repurchase program in March 2025. As of September 30, 2025, the Company repurchased 2.6 million shares for $2.71 million, with $2.29 million remaining under the program.
• Legal & Regulatory: Settled an SEC investigation regarding disclosures related to the Dovitinib NDA with a $2.5 million civil penalty paid in April 2025. The Novartis license agreement for Dovitinib was terminated in January 2024 due to material breach, resulting in immediate liabilities of approximately $5.4 million (recorded in accounts payable, convertible notes, and accrued liabilities).
• Internal Controls: Management identified a material weakness in internal control over financial reporting as of June 30, 2025, related to the accounting of the share repurchase plan. Remediation efforts are underway.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $16.9 million cash balance against the projected burn rate for the Phase II clinical trial of stenoparib.
• Novartis Liability: Confirm the status and payment schedule of the ~$5.4 million liability arising from the terminated Novartis license agreement.
• Internal Controls: Monitor the progress of remediation for the material weakness in internal controls over financial reporting identified in Q2 2025.
• Capital Needs: Assess the likelihood and terms of future capital raises given the termination of the ATM facility and the ongoing need to fund clinical trials.
• Share Repurchase Impact: Evaluate the impact of the ongoing $5 million share repurchase program on liquidity and cash reserves.